Details of the Drug

General Information of Drug (ID: DM0GQ8N)

Drug Name
Amobarbital
Synonyms
AMAL; Amasust; Amital; Amobarbitale; Amobarbitalum; Amobarbitone; Amospan; Amybal; Amylbarbitone; Amylobarbital; Amylobarbitone; Amytal; Barbamil; Barbamyl; Binoctal; Dorlotyn; Dormytal; Eunoctal; Isomyl; Isomytal; Mylodorm; Pentymal; Pentymalum; Robarb; Schiwanox; Sednotic; Somnal; Stadadorm; Sumital; Talamo; Amobarbital suppository dosage form; Amobarbitale [DCIT]; Barbamyl acid; Component of Dexamyl; Ethylisopentylbarbituric acid; Isoamylethylbarbituric acid; Amobarbital [INN:JAN]; Amobarbitalum [INN-Latin]; Component of 15-90; Component of Amo-Dextrosule; Component of Q-Caps; Isomytal (TN); Amobarbital (JP15/INN); 5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(3-methylbutyl)barbituric acid;5-Ethyl-5-isoamylbarbituric acid; 5-Ethyl-5-isoamylmalonyl urea; 5-Ethyl-5-isopentylbarbituric acid; 5-Ethyl-5-isopentylbarbitursaeure; 5-Isoamyl-5-ethylbarbituric acid; 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Indication
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [1], [2]
Therapeutic Class
Hypnotics and Sedatives
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 226.27
Topological Polar Surface Area (xlogp) 2.1
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Bioavailability
95% of drug becomes completely available to its intended biological destination(s) [3]
Chemical Identifiers
Formula
C11H18N2O3
IUPAC Name
5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione
Canonical SMILES
CCC1(C(=O)NC(=O)NC1=O)CCC(C)C
InChI
InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
InChIKey
VIROVYVQCGLCII-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2164
ChEBI ID
CHEBI:2673
CAS Number
57-43-2
DrugBank ID
DB01351
TTD ID
D0R6BR

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Antagonist [4], [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amobarbital
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Suvorexant DM0E6S3 Moderate Increased metabolism of Amobarbital caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [10]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Amobarbital caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [11]
ITI-007 DMUQ1DO Major Increased metabolism of Amobarbital caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [12]
Coadministration of a Drug Treating the Disease Different from Amobarbital (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Midostaurin DMI6E0R Moderate Increased metabolism of Amobarbital caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [13]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Amobarbital caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Amobarbital and Oliceridine. Acute pain [MG31] [15]
Ivabradine DM0L594 Moderate Increased metabolism of Amobarbital caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [16]
Dronedarone DMA8FS5 Moderate Increased metabolism of Amobarbital caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [17]
Bedaquiline DM3906J Moderate Increased metabolism of Amobarbital caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [18]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Amobarbital caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
LY2835219 DM93VBZ Moderate Increased metabolism of Amobarbital caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Amobarbital caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [21]
Tucatinib DMBESUA Moderate Increased metabolism of Amobarbital caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Palbociclib DMD7L94 Moderate Increased metabolism of Amobarbital caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [23]
Alpelisib DMEXMYK Moderate Increased metabolism of Amobarbital caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Amobarbital caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Amobarbital caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Bosutinib DMTI8YE Moderate Increased metabolism of Amobarbital caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
Macitentan DMP79A1 Moderate Increased metabolism of Amobarbital caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [28]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Amobarbital caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [29]
PF-04449913 DMSB068 Moderate Increased metabolism of Amobarbital caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [30]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Amobarbital and Dihydrocodeine. Chronic pain [MG30] [31]
Drospirenone DM1A9W3 Moderate Increased metabolism of Amobarbital caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [21]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Amobarbital caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [25]
Ulipristal DMBNI20 Moderate Increased metabolism of Amobarbital caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [16]
Osilodrostat DMIJC9X Moderate Increased metabolism of Amobarbital caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [22]
Ivacaftor DMZC1HS Moderate Increased metabolism of Amobarbital caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [32]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Amobarbital caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [33]
Vilazodone DM4LECQ Moderate Increased metabolism of Amobarbital caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [34]
Vortioxetine DM6F1PU Moderate Increased metabolism of Amobarbital caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Amobarbital and Esketamine. Depression [6A70-6A7Z] [23]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Amobarbital caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [25]
Stiripentol DMMSDOY Moderate Increased metabolism of Amobarbital caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Amobarbital caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [36]
Tazemetostat DMWP1BH Moderate Increased metabolism of Amobarbital caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [37]
Solifenacin DMG592Q Moderate Increased metabolism of Amobarbital caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [38]
Mirabegron DMS1GYT Minor Increased metabolism of Amobarbital caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [39]
Ripretinib DM958QB Moderate Increased metabolism of Amobarbital caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [23]
Avapritinib DMK2GZX Moderate Increased metabolism of Amobarbital caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [16]
Digitoxin DMWVIGP Moderate Increased metabolism of Amobarbital caused by Digitoxin mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [40]
Boceprevir DMBSHMF Moderate Increased metabolism of Amobarbital caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [41]
Telaprevir DMMRV29 Moderate Increased metabolism of Amobarbital caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [41]
MK-1439 DM215WE Moderate Increased metabolism of Amobarbital caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Fostemsavir DM50ILT Minor Increased metabolism of Amobarbital caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Etravirine DMGV8QU Moderate Increased metabolism of Amobarbital caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Amobarbital caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Maraviroc DMTL94F Moderate Increased metabolism of Amobarbital caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Penbutolol DM4ES8F Moderate Increased metabolism of Amobarbital caused by Penbutolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [44]
Nebivolol DM7F1PA Moderate Increased metabolism of Amobarbital caused by Nebivolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [45]
Levamlodipine DM92S6N Moderate Increased metabolism of Amobarbital caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [46]
Tolvaptan DMIWFRL Moderate Increased metabolism of Amobarbital caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [16]
Lesinurad DMUR64T Moderate Increased metabolism of Amobarbital caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [47]
Naloxegol DML0B41 Moderate Increased metabolism of Amobarbital caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [48]
Pemigatinib DM819JF Moderate Increased metabolism of Amobarbital caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [49]
Crizotinib DM4F29C Moderate Increased metabolism of Amobarbital caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [50]
Brigatinib DM7W94S Moderate Increased metabolism of Amobarbital caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [23]
Ceritinib DMB920Z Moderate Increased metabolism of Amobarbital caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [51]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Amobarbital caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [52]
Osimertinib DMRJLAT Moderate Increased metabolism of Amobarbital caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [53]
Capmatinib DMYCXKL Moderate Increased metabolism of Amobarbital caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [54]
Selpercatinib DMZR15V Moderate Increased metabolism of Amobarbital caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [22]
Artemether DM48QOT Moderate Increased metabolism of Amobarbital caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [23]
Idelalisib DM602WT Moderate Increased metabolism of Amobarbital caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [55]
GDC-0199 DMH0QKA Moderate Increased metabolism of Amobarbital caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [56]
IPI-145 DMWA24P Moderate Increased metabolism of Amobarbital caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [57]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Amobarbital caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [58]
Ibrutinib DMHZCPO Moderate Increased metabolism of Amobarbital caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [59]
Ponatinib DMYGJQO Moderate Increased metabolism of Amobarbital caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [23]
Vemurafenib DM62UG5 Moderate Increased metabolism of Amobarbital caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [60]
Selumetinib DMC7W6R Moderate Increased metabolism of Amobarbital caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [61]
LGX818 DMNQXV8 Moderate Increased metabolism of Amobarbital caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [62]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Amobarbital and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [63]
Ubrogepant DM749I3 Moderate Increased metabolism of Amobarbital caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [64]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Amobarbital and Lasmiditan. Migraine [8A80] [65]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Amobarbital and Flibanserin. Mood disorder [6A60-6E23] [66]
Panobinostat DM58WKG Moderate Increased metabolism of Amobarbital caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [67]
Nilotinib DM7HXWT Moderate Increased metabolism of Amobarbital caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [68]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Amobarbital caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [69]
Rolapitant DM8XP26 Moderate Increased metabolism of Amobarbital caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [70]
E-2007 DMJDYNQ Moderate Increased metabolism of Amobarbital caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [16]
Entrectinib DMMPTLH Moderate Increased metabolism of Amobarbital caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [16]
Olaparib DM8QB1D Moderate Increased metabolism of Amobarbital caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [23]
Pimavanserin DMR7IVC Moderate Increased metabolism of Amobarbital caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [71]
Macimorelin DMQYJIR Moderate Increased metabolism of Amobarbital caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [72]
Lefamulin DME6G97 Moderate Increased metabolism of Amobarbital caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [73]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Amobarbital caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [74]
Enzalutamide DMGL19D Moderate Increased metabolism of Amobarbital caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [75]
Darolutamide DMV7YFT Moderate Increased metabolism of Amobarbital caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [76]
Apremilast DMTWS9E Moderate Increased metabolism of Amobarbital caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [77]
Riociguat DMXBLMP Moderate Increased metabolism of Amobarbital caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [78]
Everolimus DM8X2EH Moderate Increased metabolism of Amobarbital caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [23]
Axitinib DMGVH6N Moderate Increased metabolism of Amobarbital caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [79]
Temsirolimus DMS104F Moderate Increased metabolism of Amobarbital caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [23]
Tofacitinib DMBS370 Moderate Increased metabolism of Amobarbital caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [23]
Avanafil DM75CXN Moderate Increased metabolism of Amobarbital caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [80]
LDE225 DMM9F25 Moderate Increased metabolism of Amobarbital caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [81]
Larotrectinib DM26CQR Moderate Increased metabolism of Amobarbital caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [23]
Trabectedin DMG3Y89 Moderate Increased metabolism of Amobarbital caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [16]
Armodafinil DMGB035 Moderate Increased metabolism of Amobarbital caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
LEE011 DMMX75K Moderate Increased metabolism of Amobarbital caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [23]
Fostamatinib DM6AUHV Moderate Increased metabolism of Amobarbital caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [22]
Apixaban DM89JLN Moderate Increased metabolism of Amobarbital caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [83]
Brilinta DMBR01X Moderate Increased metabolism of Amobarbital caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [84]
Canagliflozin DMFRM1I Moderate Increased metabolism of Amobarbital caused by Canagliflozin mediated induction of UGT. Type 2 diabetes mellitus [5A11] [23]
Saxagliptin DMGXENV Moderate Increased metabolism of Amobarbital caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [85]
Linagliptin DMWFJTR Moderate Increased metabolism of Amobarbital caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [86]
Elagolix DMB2C0E Moderate Increased metabolism of Amobarbital caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [87]
⏷ Show the Full List of 104 DDI Information of This Drug

References

1 Drug information of Amobarbital, 2008. eduDrugs.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
5 Effect of barbiturates on polyphosphoinositide biosynthesis and protein kinase C activity in synaptosomes. Neuropharmacology. 1989 Dec;28(12):1317-23.
6 Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
7 Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
8 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
11 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
12 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
13 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
14 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
15 Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8. [PMID: 6486271]
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
18 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
20 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
21 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
22 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
23 Cerner Multum, Inc. "Australian Product Information.".
24 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
25 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
26 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
27 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
28 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
29 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
30 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
31 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
32 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
33 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
34 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
35 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
36 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
37 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
38 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
39 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
40 Cardoso MT, Carvalhas ML. Effects of phenobarbital on digitoxin metabolism in guinea-pig liver slices. Xenobiotica. 1980;10(10):779-784. [PMID: 7456493]
41 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
42 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
43 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
44 Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C "Influence of pentobarbital on metoprolol plasma levels." Clin Pharmacol Ther 26 (1979): 326-9. [PMID: 466926]
45 Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
46 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
47 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
48 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
49 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
50 Cerner Multum, Inc. "Canadian Product Information.".
51 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
52 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
53 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
54 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
55 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
56 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
57 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
58 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
59 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
60 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
61 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
62 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
63 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
64 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
65 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
66 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
67 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
68 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
69 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
70 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
71 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
72 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
73 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
74 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
75 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
76 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
77 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
78 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
79 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
80 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
81 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
82 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
83 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
84 Canadian Pharmacists Association.
85 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
86 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
87 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.